Ipswich Hospital

Ipswich IP4 5PD

2 studies enrolling now · 13 studies all time

What they study most

Ankylosing Spondylitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Atherosclerotic Cardiovascular Disease (ASCVD), Breast Cancer, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Diabetes Mellitus, Type 1, Fracture, Infections, Melanoma, Metabolic Dysfunction-Associated Steatotic Liver Disease, Microscopic Polyangiitis

Studies at this site

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• Exactech Shoulder Post Market Clinical Follow-up Study — Recruiting now
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer — Completed
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma — Completed
• Rituximab Vasculitis Maintenance Study — Completed
• BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab — Stopped early
• The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed
• A Degarelix Trial in Patients With Prostate Cancer — Stopped early
• A Trial of Degarelix in Patients With Prostate Cancer — Completed